Deeply invasive candidiasis

Luis Ostrosky-Zeichner, John H. Rex, John Bennett, Bart Jan Kullberg

Research output: Contribution to journalArticle

Abstract

The incidence of invasive candidiasis is on the rise because of increasing numbers of immunocompromised hosts and more invasive medical technology. Recovery of Candida spp from several body sites in a critically ill or immunocompromised patient should raise the question of disseminated disease. Although identification to the species level and antifungal susceptibility testing should guide therapy, at this time amphotericin B preparations are the usual initial therapy for severe life-threatening disease. Azole therapy has an expanding body of evidence that proves it is as effective as and safer than amphotericin B therapy. Some forms of candidiasis (eg, those with ocular, bone, or heart involvement) require a combined medical and surgical approach.

Original languageEnglish (US)
Pages (from-to)821-835
Number of pages15
JournalInfectious Disease Clinics of North America
Volume16
Issue number4
DOIs
StatePublished - Dec 2002
Externally publishedYes

Fingerprint

Invasive Candidiasis
Immunocompromised Host
Amphotericin B
Azoles
Candidiasis
Therapeutics
Candida
Critical Illness
Technology
Bone and Bones
Incidence

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Ostrosky-Zeichner, L., Rex, J. H., Bennett, J., & Kullberg, B. J. (2002). Deeply invasive candidiasis. Infectious Disease Clinics of North America, 16(4), 821-835. https://doi.org/10.1016/S0891-5520(02)00034-X

Deeply invasive candidiasis. / Ostrosky-Zeichner, Luis; Rex, John H.; Bennett, John; Kullberg, Bart Jan.

In: Infectious Disease Clinics of North America, Vol. 16, No. 4, 12.2002, p. 821-835.

Research output: Contribution to journalArticle

Ostrosky-Zeichner, L, Rex, JH, Bennett, J & Kullberg, BJ 2002, 'Deeply invasive candidiasis', Infectious Disease Clinics of North America, vol. 16, no. 4, pp. 821-835. https://doi.org/10.1016/S0891-5520(02)00034-X
Ostrosky-Zeichner L, Rex JH, Bennett J, Kullberg BJ. Deeply invasive candidiasis. Infectious Disease Clinics of North America. 2002 Dec;16(4):821-835. https://doi.org/10.1016/S0891-5520(02)00034-X
Ostrosky-Zeichner, Luis ; Rex, John H. ; Bennett, John ; Kullberg, Bart Jan. / Deeply invasive candidiasis. In: Infectious Disease Clinics of North America. 2002 ; Vol. 16, No. 4. pp. 821-835.
@article{aaa8e8eddfe447e48096a555ec8457d2,
title = "Deeply invasive candidiasis",
abstract = "The incidence of invasive candidiasis is on the rise because of increasing numbers of immunocompromised hosts and more invasive medical technology. Recovery of Candida spp from several body sites in a critically ill or immunocompromised patient should raise the question of disseminated disease. Although identification to the species level and antifungal susceptibility testing should guide therapy, at this time amphotericin B preparations are the usual initial therapy for severe life-threatening disease. Azole therapy has an expanding body of evidence that proves it is as effective as and safer than amphotericin B therapy. Some forms of candidiasis (eg, those with ocular, bone, or heart involvement) require a combined medical and surgical approach.",
author = "Luis Ostrosky-Zeichner and Rex, {John H.} and John Bennett and Kullberg, {Bart Jan}",
year = "2002",
month = "12",
doi = "10.1016/S0891-5520(02)00034-X",
language = "English (US)",
volume = "16",
pages = "821--835",
journal = "Infectious Disease Clinics of North America",
issn = "0891-5520",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Deeply invasive candidiasis

AU - Ostrosky-Zeichner, Luis

AU - Rex, John H.

AU - Bennett, John

AU - Kullberg, Bart Jan

PY - 2002/12

Y1 - 2002/12

N2 - The incidence of invasive candidiasis is on the rise because of increasing numbers of immunocompromised hosts and more invasive medical technology. Recovery of Candida spp from several body sites in a critically ill or immunocompromised patient should raise the question of disseminated disease. Although identification to the species level and antifungal susceptibility testing should guide therapy, at this time amphotericin B preparations are the usual initial therapy for severe life-threatening disease. Azole therapy has an expanding body of evidence that proves it is as effective as and safer than amphotericin B therapy. Some forms of candidiasis (eg, those with ocular, bone, or heart involvement) require a combined medical and surgical approach.

AB - The incidence of invasive candidiasis is on the rise because of increasing numbers of immunocompromised hosts and more invasive medical technology. Recovery of Candida spp from several body sites in a critically ill or immunocompromised patient should raise the question of disseminated disease. Although identification to the species level and antifungal susceptibility testing should guide therapy, at this time amphotericin B preparations are the usual initial therapy for severe life-threatening disease. Azole therapy has an expanding body of evidence that proves it is as effective as and safer than amphotericin B therapy. Some forms of candidiasis (eg, those with ocular, bone, or heart involvement) require a combined medical and surgical approach.

UR - http://www.scopus.com/inward/record.url?scp=0036903057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036903057&partnerID=8YFLogxK

U2 - 10.1016/S0891-5520(02)00034-X

DO - 10.1016/S0891-5520(02)00034-X

M3 - Article

C2 - 12512183

AN - SCOPUS:0036903057

VL - 16

SP - 821

EP - 835

JO - Infectious Disease Clinics of North America

JF - Infectious Disease Clinics of North America

SN - 0891-5520

IS - 4

ER -